Overview
Evolving Recommendations and Strategies for Vaccine Selection in Populations at Risk for Severe Influenza-related Illness
Vaccine Selection Touchpoint
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Are you current with the recent data and guidance on influenza vaccine selection based on age, risk factors, and individual characteristics? Do you know about the most recently approved and emerging vaccines? Access this comprehensive 60-minute, CME Touchpoint that will walk you through an overview of novel and emerging influenza vaccines and their potential roles in preventative medicine. This Touchpoint is enhanced with videos, graphics, and supplemental resources to provide you with the most up to date information on how to best prevent influenza.
This activity is intended for primary care physicians, internists, pediatricians, geriatricians, pharmacists, and other clinicians who manage patients for whom influenza vaccination is recommended.
Although vaccines are among the most cost-effective preventive services, nearly 45,000 individuals in the U.S. die each year of vaccine-preventable diseases or associated complications. Fortunately, advances in the fields of influenza virology and immunity have created new opportunities to improve vaccine efficacy. Given the complex guidance and emerging data on different influenza vaccines, clinicians require education to guide decisions on vaccine selection as well as to improve understanding of influenza vaccine developments as the number of potential approaches expand and improvements in the magnitude and duration of immune responses are realized.
Upon completion of this activity, participants will be able to:
• List available influenza vaccines and recommendations for use
• Interpret patient and clinical factors to select among the influenza vaccines
• Discuss the latest safety and efficacy data supporting the use of EIV in patients at high-risk for influenza
• Describe ongoing investigations to improve the production and efficacy of influenza vaccines
• List available influenza vaccines and recommendations for use
• Interpret patient and clinical factors to select among the influenza vaccines
• Discuss the latest safety and efficacy data supporting the use of EIV in patients at high-risk for influenza
• Describe ongoing investigations to improve the production and efficacy of influenza vaccines
Expanding Number of Options for Influenza Vaccination
• Morbidity and mortality of influenza
• Available influenza vaccines
• Vaccine efficacy and effectiveness across diverse patients
• Current ACIP recommendations
• Morbidity and mortality of influenza
• Available influenza vaccines
• Vaccine efficacy and effectiveness across diverse patients
• Current ACIP recommendations
Factoring Patient and Clinical Characteristics into Vaccine Selection
• Evidence in the elderly population
• Pharmacoeconomic data
• Immunosuppression and other high-risk groups
• Addressing vaccine hesitancy
Novel Approaches to Vaccine Development
• Current limitations and challenges
• Different approaches to production
• mRNA and self-amplifying mRNA
• Need for a universal vaccine
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an unrestricted educational grant from CSL Seqirus.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Michael Hogue, PharmD, FAPhA, FNAP
Dean and Professor
Loma Linda University - School of Pharmacy
Professor of Preventive Medicine, School of Medicine
Director, Center for Interprofessional Education & Practice
Loma Linda University
Loma Linda, CA
Dean and Professor
Loma Linda University - School of Pharmacy
Professor of Preventive Medicine, School of Medicine
Director, Center for Interprofessional Education & Practice
Loma Linda University
Loma Linda, CA
Margot Savoy, MD, MPH, FAAFP
Associate Professor of Family & Community Medicine
Associate Professor of Urban Bioethics & Population Health
Lewis Katz School of Medicine at Temple University
Philadelphia, PA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Michael Hogue, PharmD, FAPhA, FNAP
No financial relationships to disclose
Margot Savoy, MD, MPH, FAAFP
Advisory Panel: Eisai
Independent Contractor: Merck & Co., Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: universal vaccines as well as mRNA and saRNA vaccines in development for influenza
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Michelle Forcier at mforcier@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.0 contact hours.
ACPE Universal Activity Number: 0396-0000-22-059-H01-P
Activity Type: Application
Release Date: October 31, 2022
Expiration Date: October 31, 2023
